<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008926</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC18.0262 (NIPA)</org_study_id>
    <nct_id>NCT05008926</nct_id>
  </id_info>
  <brief_title>The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients</brief_title>
  <acronym>NIPA</acronym>
  <official_title>The NIPA Study: A Randomized Double-blind Control Clinical Trial Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impaired gastrointestinal transit (IGT) especially constipation, is common among patients&#xD;
      under mechanical ventilation, occurring in up to 80 % of the patients during the first week,&#xD;
      and has been associated with worse outcome in intensive care unit (ICU). Although IGT in&#xD;
      critically ill patients is multifactorial and some components are due to complex disease,&#xD;
      there is increasing evidence that exogenous opioids contribute to bowel dysmotility.&#xD;
&#xD;
      Sedatives and especially opioids are largely used in the brain injured population to control&#xD;
      intracranial pression, reduce metabolic rate, manage or prevent seizures, and improve&#xD;
      mechanical ventilator synchrony. Therefore, brain injured patients are particularly at risk&#xD;
      to develop IGT. The occurrence of IGT is associated with adverse outcomes in intensive care&#xD;
      unit. Both gastric reflux and impaired peristaltic contractions are associated with&#xD;
      ventilator-acquired pneumonia.&#xD;
&#xD;
      The actual challenge is to prevent motility disorders before it occurs. A preventive strategy&#xD;
      could in turn reduce the occurrence of complications related to impaired gastrointestinal&#xD;
      transit such as ventilator-acquired pneumonia, bacteremia etc. It could also reduce the&#xD;
      complications of feed intolerance and thus reduce morbidity and mortality in ICU.&#xD;
&#xD;
      Naloxegol is a polyethylene glycol derivative of naloxol, which is a derivative of naloxone&#xD;
      and a peripherally acting µ-opioid receptor antagonist. Contrary to naloxone, naloxegol has a&#xD;
      very low penetration into the central nervous system, therefore it could be a relevant option&#xD;
      for ileus prevention without the risk of impaired sedation.&#xD;
&#xD;
      The aim of our study is to assess the efficacy of the administration of naloxegol on the&#xD;
      onset of early constipation and early ventilator-acquired pneumonia in brain injured patients&#xD;
      receiving opioids for analgosedation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, double-blind, placebo-controlled experimental study of Naloxegol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of bowel movement</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ventilator-acquired pneumonia</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient-days who received the daily calorie goal (25 Kcal / kg / day)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who required one or more administration of erythromycin and / or metoclopramide for vomiting occurring during enteral feeding</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who received one or more rectal laxative for constipation</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in days of occurrence of the first bowel movement (in case of late constipation)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with ventilator-acquired pneumonia after D7 of invasive mechanical ventilationventilation (after D7 of invasive mechanical ventilation)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without invasive mechanical ventilation</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization in intensive care unit</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale Extended Score</measure>
    <time_frame>6 month</time_frame>
    <description>The Glasgow Outcome Scale (GOS) is a comprehensive assessment scale for functional outcome that classifies a patient's condition into one of five categories: Death, Vegetative State, Severe Handicap, Moderate Handicap or Good Recovery. The extended GOS scale (GOSE) allows a more detailed classification into eight categories, thanks to a subdivision into two levels (lower and higher) of the categories &quot;severe handicap&quot;, &quot;moderate handicap&quot; and &quot;good recovery&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who experienced an episode of intracranial hypertension requiring targeted temperature management, barbiturates, or decompression craniectomy.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Brain Injuries</condition>
  <arm_group>
    <arm_group_label>Naloxegol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.&#xD;
Management of constipation and gastroparesis according to the recommendations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of the placebo according to the same procedures as the experimental arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxegol</intervention_name>
    <description>Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.</description>
    <arm_group_label>Naloxegol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of the placebo according to the same procedures as the experimental arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ to 18 years old&#xD;
&#xD;
          2. Admission to intensive care unit for traumatic brain injury or subarachnoid hemorrhage&#xD;
             without other life-threatening injury&#xD;
&#xD;
          3. Patients under sedation with administration of opiate-agonists, μ receptor agonists&#xD;
             (Sufentanil, Fentanyl, Remifentanil, Morphine) for less than 24 hours&#xD;
&#xD;
          4. Expected duration of invasive mechanical ventilation and sedation of 72 hours or more&#xD;
&#xD;
          5. Intracranial pressure monitoring&#xD;
&#xD;
          6. Enteral feeding by oro / nasogastric tube&#xD;
&#xD;
          7. Affiliated or beneficiary of the French social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who received opioids for more than 24 hours&#xD;
&#xD;
          2. Patient with refractory intracranial hypertension at the time of inclusion:&#xD;
             intracranial hypertension requiring therapy other than analgo-sedation (thiopental,&#xD;
             targeted temperature management, decompressive craniectomy)&#xD;
&#xD;
          3. Acute or chronic renal failure with creatinine clearance &lt;60ml / min&#xD;
&#xD;
          4. Known or suspected acute gastrointestinal obstruction&#xD;
&#xD;
          5. Risk of digestive perforation:&#xD;
&#xD;
               -  history of peptic ulcer&#xD;
&#xD;
               -  Crohn's disease&#xD;
&#xD;
               -  Ogilvie syndrome&#xD;
&#xD;
               -  acute diverticulitis&#xD;
&#xD;
               -  infiltrating gastrointestinal tumor&#xD;
&#xD;
               -  recurrent or advanced ovarian cancer&#xD;
&#xD;
               -  peritoneal metastasis&#xD;
&#xD;
               -  recent abdominal trauma with risk of digestive perforation&#xD;
&#xD;
          6. Concomitant treatment with a strong or moderate inhibitory effect of CYP 3A4 (For&#xD;
             example: clarithromycin, ketaconazole, itraconazole, telithromycin, ritonavir,&#xD;
             indinavir, saquinavir) or with a strong inducing effect (carbamazepin, rifampicin,&#xD;
             millepertuis)&#xD;
&#xD;
          7. Concomitant treatment with vascular endothelial growth factor (VEGF) inhibitor&#xD;
&#xD;
          8. Allergy to Naloxegol or one of its excipients&#xD;
&#xD;
          9. Recent history of myocardial infarction within the past 6 months, symptomatic&#xD;
             congestive cardiovascular disease, QT ≥ 500 msec&#xD;
&#xD;
         10. Patient with a medical decision for rapid palliative care&#xD;
&#xD;
         11. Pregnancy and / or breastfeeding&#xD;
&#xD;
         12. Child Pugh C stage cirrhosis&#xD;
&#xD;
         13. Patient under legal protection or deprived of liberty&#xD;
&#xD;
         14. Patient with another life-threatening injury&#xD;
&#xD;
         15. History of clinically important alterations of the blood-brain barrier: primary brain&#xD;
             tumors, metastasis or other inflammatory pathologies in the CNS, active multiple&#xD;
             sclerosis, Alzheimer's disease at an advanced stage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Huet, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Huet, PU-PH</last_name>
    <phone>+33 2 98 34 72 88</phone>
    <email>olivier.huet@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Aries, PH</last_name>
    <phone>+33 2 98 34 72 88</phone>
    <email>philippe.aries@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Aries, PH</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Aries, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yannick Hourmant, PH</last_name>
    </contact>
    <investigator>
      <last_name>Yannick Hourmant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpétrière (APHP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent Degos, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Degos, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired gastrointestinal transit</keyword>
  <keyword>Subarachnoid Hemorrhage</keyword>
  <keyword>Traumatic brain injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning five years and ending fifteen years following the final study report completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

